NCT02218203View on ClinicalTrials.gov

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Central Neuropathic PainAllodyniaSpinal Cord Injury
Interventions
DRUG

Dextromethorphan

Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)

DRUG

Lidocaine

0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)

DRUG

Placebo (Dextromethorphan)

0mg Dextromethorphan

DRUG

Placebo (Lidocaine)

0mg/kg LBM Lidocaine

Trial Locations (1)

02115

Translational Pain Research, Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT02218203 - Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial | Biotech Hunter | Biotech Hunter